# US 2026/0091132 A1 · Gene therapies for usher syndrome (ush1b)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0091132 A1
- Document ID: US20260091132A1
- Status: Published application
- Kind: A1
- Application number: 19/261,632
- Filed: 2025-07-07
- Published: 2026-04-02
- Earliest claimed: 2019-04-19
- Assignees: University of Massachusetts
- Applicants: University of Massachusetts
- Inventors: Hemant Khanna
- Web page: https://patentgrep.com/patent/US20260091132A1

## CPC

- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A01K 67/0276: Knock-out vertebrates
- C07K 14/4716: {Muscle proteins, e.g. myosin, actin}
- A01K 2217/072: maintaining or altering function, i.e. knock in
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2227/105: Murine
- A01K 2227/40: Fish
- A01K 2267/0306: Animal model for genetic diseases
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Aspects of the disclosure relate to compositions and methods useful for delivering minigenes to a subject. Accordingly, the disclosure is based, in part, on isolated nucleic acids and gene therapy vectors, such as viral (e.g., rAAV) vectors, comprising one or more gene fragments encoding a therapeutic gene product, such as a protein or peptide (e.g., a minigene). In some embodiments, the disclosure relates to gene therapy vectors encoding a USH1B protein (e.g., the gene product of USH1B, also referred to as MY07A) or a portion thereof. In some embodiments, compositions described by the disclosure are useful for treating diseases associated with mutations in the USH1B (MY07A) gene, for example Usher Syndrome.

## Claims

### Claim 1

An isolated nucleic acid comprising a transgene encoding a USH1B minigene having the nucleic acid sequence set forth in any one of SEQ ID NOs: 3-14.

### Claim 2 (depends on 1)

The isolated nucleic acid of claim 1, wherein the transgene further comprises a promoter operably linked to the USH1B minigene sequence, wherein the promoter is a constitutive promoter, inducible promoter, or a tissue-specific promoter, optionally wherein the tissue specific promoter is a photoreceptor-specific promoter.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The isolated nucleic acid of claim 1, wherein the transgene is flanked by adeno-associated virus (AAV) inverted terminal repeats (ITRs).

### Claim at position 5

5-6. (canceled)

### Claim 7

An isolated nucleic acid comprising a transgene having a nucleic acid sequence encoding a USH1B protein, wherein the USHB1 protein comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 15-26.

### Claim 8 (depends on 7)

The isolated nucleic acid of claim 7, wherein the transgene further comprises a promoter operably linked to the nucleic acid sequence encoding the USH1B protein, wherein the promoter is a constitutive promoter, inducible promoter, or a tissue-specific promoter, optionally wherein the tissue specific promoter is a photoreceptor-specific promoter.

### Claim 9

(canceled)

### Claim 10 (depends on 7)

The isolated nucleic acid of claim 7, wherein the transgene is flanked by adeno-associated virus (AAV) inverted terminal repeats (ITRs).

### Claim 11 (depends on 10)

The isolated nucleic acid of claim 10, wherein at least one of the ITRs is an AAV2 ITR.

### Claim 12 (depends on 10)

The isolated nucleic acid of claim 10, wherein at least one ITR lacks a terminal resolution site, optionally wherein the ITR is a ΔITR.

### Claim 13 (depends on 1)

A vector comprising the isolated nucleic acid of claim 1.

### Claim 14 (depends on 13)

The vector of claim 13, wherein the vector is a plasmid DNA, closed-linear DNA, lipid/DNA nanoparticle, or a viral vector.

### Claim 15 (depends on 14)

The vector of claim 14, wherein the viral vector is an adeno-associated virus (AAV) vector, adenoviral (Ad) vector, lentiviral vector, retroviral vector, or Baculovirus vector.

### Claim 16 (depends on 1)

A host cell comprising the isolated nucleic acid of claim 1.

### Claim 17 (depends on 16)

The host cell of claim 16, wherein the cell is a mammalian cell, bacterial cell, yeast cell, or insect cell.

### Claim 18 (depends on 1)

A recombinant adeno-associated virus (rAAV) comprising:
(i) the isolated nucleic acid of claim 1; and
(ii) an AAV capsid protein.

### Claim 19 (depends on 18)

The rAAV of claim 18, wherein the capsid protein has a tropism for ocular cells.

### Claim 20 (depends on 18)

The rAAV of claim 18, wherein the capsid protein is AAV8 capsid protein.

### Claim 21 (depends on 18)

The rAAV of claim 18, wherein the rAAV is formulated for delivery to the eye, optionally wherein the rAAV is formulated for delivery to photoreceptor cells or retinal pigmented epithelium (RPE).

### Claim 22 (depends on 1)

A composition comprising the isolated nucleic acid of claim 1 and a pharmaceutically acceptable excipient.

### Claim 23 (depends on 1)

A method for delivering a transgene to a cell, the method comprising administering the isolated nucleic acid of claim 1 to a cell.

### Claim at position 23

24-27. (canceled)

### Claim 28 (depends on 1)

A method for treating Usher Syndrome in a subject in need thereof, the method comprising administering the isolated nucleic acid of claim 1 to the subject.

### Claim at position 25

29-32. (canceled)
